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Abstract 
Background: Abdominal leiomyosarcoma arising from the mesentery is a rare malignancy. It is an aggressive entity 
with an overall 5 year survival rate between 20 and 30 %. Surgical resection is the cornerstone of primary treatment 
and may be curative for localized disease. However, patients often develop intra-abdominal relapse and/or metastatic 
disease. If surgical resection is not feasible, palliative chemotherapy is the treatment of choice. However, there are no 
clear guidelines regarding chemotherapy; neither in the adjuvant nor advanced setting.
Case presentation: We present a 40 year-old woman, with a mesenteric leiomyosarcoma, who underwent radical 
tumor resection and did not receive adjuvant oncological therapy. Three months postoperatively, she developed 
metastatic disease to the lungs and liver. After multidisciplinary assessment she received an unconventional histo-
logical-subtype-tailored chemotherapy comprising 3–4 regimens. Initially, there was a decrease both in number and 
size of metastases. Ultimately, an almost complete radiological response was seen. Subsequent surgical resection and 
radiofrequency ablation of residual metastatic foci in the liver and lung brought her into complete clinical remission. 
She is presently tumor free, 36 months following diagnosis of metastatic disease.
Conclusions: To our knowledge, this is the first report of a patient with metastatic mesenteric leiomyosarcoma who 
is in complete clinical and radiological long-term remission following very aggressive multimodal treatment; includ-
ing intense poly-drug chemotherapy and without any demonstrable long-term side effects. Given the rarity of mes-
enteric leiomyosarcoma and lack of guidelines regarding oncological therapy, we suggest that multimodal therapy 
including aggressive chemotherapy, guided by a multidisciplinary team, is essential to achieve an optimal outcome.
Keywords: Leiomyosarcoma, Mesenteric, Abdominal, Histological-subtype, Chemotherapy, Metastases, Multimodal
© 2016 Varghese et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Leiomyosarcoma (LMS) represents between 10 and 20 % 
of all newly diagnosed soft tissue sarcomas [1]. It is clas-
sified based on anatomical site of origin, a factor that is 
important for outcome and prognosis [2]. Abdominal 
LMS is highly aggressive with an overall 5  year survival 
rate between 20 and 30  % [3]. Although histologically 
similar, the different anatomic variants of abdominal 
LMS have varying clinical behaviour and differ in 
prognosis [4]. Surgical resection is the cornerstone of 
curative treatment for localized disease if adequate mar-
gins are obtained [1, 5]. However, this is often not pos-
sible due to anatomical restrictions and large tumor size 
at diagnosis. Moreover, LMS tends to metastasize, most 
commonly to the lungs and liver. Unfortunately, there 
are no clear guidelines regarding the role of oncological 
treatment; neither in the primary nor metastatic setting 
[5]. In fact, almost all patients with metastatic disease 
are considered incurable and, thus, offered only palliative 
treatment.
Here, we present a patient with an abdominal LMS, 
specifically a mesenteric LMS. This is a rare malignancy, 
Open Access
Clinical Sarcoma Research
*Correspondence:  Mercy.verghese@gmail.com 
7 Department of Surgery, Nordland Hospital, 8092 Bodoe, Norway
Full list of author information is available at the end of the article
Page 2 of 7Varghese et al. Clin Sarcoma Res  (2016) 6:2 
with only a few cases reported in the literature [6–9]. The 
LMS was surgically resected with an R0 margin and no 
adjuvant oncological therapy was given. Unfortunately, 
the patient developed metastatic disease both to the liver 
and lungs. Histological evaluation of metastases revealed 
a highly malignant, pleomorphic sarcoma that resembled 
her primary tumor, but was not morphologically identi-
cal. It was categorized as dedifferentiated LMS [3, 10]. An 
aggressive multimodal therapeutic strategy was chosen, 
including staggered intensive chemotherapy tailored to 
the histological-subtype of the metastasis [11]. Presently, 
she is in complete clinical remission about 36 months fol-
lowing diagnosis of metastatic disease and without any 
demonstrable long-term side effects from chemotherapy.
Case report
Our patient is a 40 year old woman who had no signifi-
cant medical history except for an appendectomy when 
she was 20  years-old. She presented with a two-month 
history of left sided abdominal pain accompanied by 
abdominal discomfort and distention. Additionally, she 
suffered from nausea and vomiting without any changes 
in stool pattern.
On physical examination, a large palpable mass was 
detected in the left quadrant. This mass was very tender 
upon palpation, but there were no signs of peritonitis. 
Blood tests revealed increased acute phase proteins and 
reduced haemoglobin but were otherwise unremark-
able. Computerized tomography (CT) of the abdomen 
revealed an intraperitoneal tumor in the left quadrant 
measuring 8  ×  7  cm axially and 7  cm craniocaudally 
(Fig. 1a). The tumor was closely related to the descending 
colon and small intestine and revealed heterogenous con-
trast enhancement with necrotic areas (Fig.  1b). There 
was no pelvic or retroperitoneal adenopathy, though 
some ascites was seen in the pelvis minor. A sarcoma was 
suspected and the patient was referred to the Section for 
Sarcoma at The Norwegian Radium Hospital.
About two weeks later, the patient was operated via a 
midline laparotomy. The tumor, which was partly adher-
ent to the sigmoid mesocolon, was removed en bloc 
together with 15  cm of small intestine and colon. An 
antiperistaltic side-to-side-anastomosis was established 
at the splenic flexure as well as a small intestinal anasto-
mosis about 120 cm proximal to the ileocaecal valve. No 
intraperitoneal metastases were seen, but tumor perfora-
tion to the peritoneal cavity and resulting bloody ascites 
was documented perioperatively. Despite this high risk 
for tumor relapse, no adjuvant therapy was given to the 
patient in line with guidelines regarding adjuvant therapy 
for abdominal LMS [5].
Histopathological investigations revealed that the 
resected tumor measured 11 ×  9 ×  7  cm, was well cir-
cumscribed and without infiltration of the small or large 
intestine. However, the tumor diffusely invaded the sero-
sal surface. More than 50 % of the tumor showed necrosis 
macroscopically. Histologically, the tumor consisted of 
pleomorphic, spindle cells with eosinophilic cytoplasm 
and focally cigar shaped nuclei resembling a high grade, 
pleomorphic leiomyosarcoma. Up to 14  mitoses per 10 
Fig. 1 CT of the primary LMS. CT of the abdomen and pelvis showing an intraperitoneal tumor in the left quadrant measuring 8 × 7 × 7 cm (a 
coronal section). The tumor is located in the mesentery and is in close relation to both the small bowel and the sigmoid colon (b axial section). The 
low-density region within the tumor indicates necrosis
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high power fields (1734 mm2) were found (French malig-
nancy grade 3) (Fig. 2a, b). No invasion of blood vessels 
was seen. Immunohistochemical examination showed 
distinct, focal positivity for caldesmon, SMA and desmin, 
supporting the diagnosis of LMS (Fig. 2 c–e).
About three months after the operation, the patient 
experienced intermittent abdominal pain. No local tumor 
recurrence was seen on the CT of the abdomen, but mul-
tiple contrast enhancing lesions, typical for metastases, 
were seen in the liver, the largest measuring close to 3 cm 
(Fig. 3a). Chest CT revealed multiple round, well-circum-
scribed lesions in both lungs consistent with metastases 
(Fig.  3b). Biopsy of a liver lesion confirmed metastatic 
disease and showed only large, pleomorphic cells (Fig. 3a 
insert) consistent with a highly malignant pleomorphic 
sarcoma. After multidisciplinary assessment, we decided 
to treat the patient with 6 cycles of doxorubicin (50 mg/
m2, for the first treatment and 75  mg/m2 for the other 
cycles) and ifosfamide (5 g/m2) with granulocyte colony-
stimulating factor (G-CSF) given at 3  weeks interval. 
The patient showed a radiological response, exhibiting 
partial remission with a reduction in size and number 
of liver and lung metastases (Fig.  4). No new metasta-
ses were seen. Moreover, her side effects of treatment 
were surprisingly modest. Hence, to further enhance the 
chemotherapeutic effect, we added 5 cycles of weekly 
doxorubicin monotherapy (20  mg) and 6 cycles with 
gemcitabine 675  mg/m2 days 1 and 8 with docetaxel 
75  mg/m2 on day 8 and G-CSF on day 9 (every three 
weeks). This induced a further reduction in the number 
and size of metastases in the liver and lungs. Due to side 
effects with water retention and muscle pain we switched 
to 3 cycles of high dose ifosfamide 12 g/m2. Subsequent 
radiological assessment confirmed an almost complete 
radiological response to this intense schedule of chemo-
therapies (Fig. 4). 
After a multidisciplinary discussion, we considered 
the remaining visible lesions in the lungs and liver to be 
resectable. Therefore, the patient underwent combined 
left hepatectomy in combination with radiofrequency 
ablation of metastatic foci in the right liver lobe, followed 
by a thoracoscopic wedge resection of metastasis in the 
right lung. The rationale of removing metastases was to 
decrease tumor burden, as this has been shown to pro-
long disease-free survival and probably also overall sur-
vival, similar to what is seen in patients who undergo 
resection of metastases limited to the lungs [12]. This 
combination of surgery and/or radiofrequency ablation 
of residual lesions was performed to improve chances 
of long-term clinical remission, as there was no evi-
dence of tumor outside the liver and lungs. An imme-
diate postoperative MRI of the abdomen showed three 
Fig. 2 Histopathology of tumor. Histopathological analysis of primary tumor revealed pleomorphic, spindle cells (a) and pleomorphic cells (b) with 
eosinophilic cytoplasm consistent with a high grade, pleomorphic leiomyosarcoma. Immunohistochemical examination showed distinct, focal 
positivity for SMA (c), desmin (d) and H-caldesmon (e), markers that are characteristic for LMS
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residual lesions in the liver which were not visible on 
the perioperative ultrasound and suspicious subcutane-
ous lesions near the midline laparotomy scar. A repeat 
laparotomy was then performed in which the abdominal 
scar was removed in combination with ultrasound/MRI-
image fusion guided re-ablation of the liver. Histological 
Fig. 3 CT of metastatic disease. Axial CT of the abdomen and thorax. Multiple contrast-enhancing lesions in the liver with irregular borders typical 
for metastases (a). Histopathological analysis of a liver metastasis revealed only large, pleomorphic cells (a inset) consistent with a highly malignant 
dedifferentiated pleomorphic sarcoma. CT of thorax showing multiple round, well-circumscribed lung lesions consistent with metastases. The 
ground-glass opacity around the lesions may be caused by hemorrhage (b)
Fig. 4 CT showing radiological response. Axial CT of the thorax and abdomen showing almost complete radiological response after histological 
subtype-specific chemotherapy. A small metastatic lesion measuring 5 × 6 mm (a, arrow) and no other visible metastatic foci in the lungs or the 
liver (b) are seen after chemotherapy
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evaluation of the aforementioned lesions revealed only 
fibrotic changes with no viable tumor cells. Postopera-
tively, the patient received 2 cycles of weekly doxoru-
bicin 20 mg due to a strong desire from the patient. Post 
operative CT of the abdomen and thorax revealed only 
postoperative changes in the liver and lungs. A complete 
outline and scheduling of the various chemotherapies are 
displayed in Fig. 5.
Five months after surgery for metastatic disease, the 
patient developed abdominal pain and constipation. CT 
of the abdomen and thorax revealed only postopera-
tive changes. Moreover, upper and lower endoscopy was 
unremarkable. A contrast study showed no pathology, 
only stenosis of the small intestine, which was dilatated, 
and the patient showed symptomatic relief after laxative 
therapy. The patient is presently in clinical remission, 36  
months following diagnosis of metastatic disease.
Discussion
Abdominal LMS
Mesenteric LMS was first described in 1963 [13] and 
is most likely derived from the smooth muscle cells 
of blood vessels in the mesentery [3]. It is an aggres-
sive disease and approximately half of all patients will 
develop distant metastases despite adequate local con-
trol [14]. The overall 5 year survival rate is only 20–30 % 
[3], partly because mesenteric LMS often remains unde-
tected until late in the course of disease development, 
due to the large available space of the abdominal cav-
ity. As in the case of our patient, abdominal distension 
and discomfort are common presenting symptoms [1]. 
Additionally, altered bowel movements and weight 
loss are also seen. Blood tests are non-specific but may 
reveal anaemia [1] and elevated acute phase proteins. 
Radiological assessment is mandatory for preoperative 
evaluation of tumor location, dimensions and relation 




Surgery is the cornerstone of treatment and is the only 
therapeutic modality proven to provide cure [5]. However, 
complete resection is often difficult due to large tumor size 
at presentation and recent studies have shown that resec-
tion margins may be the only significant predictor of local 
recurrence [4, 15]. Moreover, complete primary surgical 
resection is critical for achieving the best overall outcome 
[16]. Other factors include tumor depth, histological grade, 
and metastasis at presentation [15, 17]. The role of adjuvant 
chemotherapy in localized disease is not established and 
therefore is not standard treatment [5]. It can be proposed 
to high-risk patients, after multidisciplinary assessment or 
within clinical trials. In keeping with current guidelines, 
our patient did not receive adjuvant treatment.
Metastatic disease
Chemotherapy
When our patient developed metastatic disease, a core 
needle biopsy of a liver metastasis was obtained. Though 
the biopsy material was limited, a highly malignant 
tumor, displaying only large pleomorphic cells similar to 
the cells focally present in the primary tumor, was seen. 
This may suggest a histological-subtype that had evolved 
into a dedifferentiated phenotype compared to the pri-
mary tumor. This was the reason for choosing to add 
ifosfamide, rather than dacarbazine, to the initial regi-
men [18]. Such biological heterogeneity is documented 
between primary and metastatic disease in a number of 
malignancies [19]. Patients with pleomorphic or dediffer-
entiated LMS have a particularly poor prognosis, with a 
metastatic rate of 89 % [10].
The choice of chemotherapeutic agents depend on 
several factors including histological-subtype, age, co-
morbidity and expected tolerance of side effects. Our 
present knowledge regarding chemotherapy of LMS is 
mainly based on non-randomized phase II studies or 
Fig. 5 A timeline of events and chemotherapy schedules. Diagnosis of metastatic disease designated as time point zero and denoted as 0 months 
(0 mo). Milestones within response evaluation and interventional therapy denoted as running months from zero time point. Abbreviations of 
chemotherapeutic drugs: Doxorubicin and Ifosfamide (Doxo + Ifo), Low-dose Doxorubicin (LD Doxo), Gemcitabine and Docetaxel (Gem + Doce), 
High-dose Ifosfamide (HD Ifo)
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retrospective case series [11]. Furthermore, the rarity and 
heterogeneity of soft tissue sarcomas, as well as the high 
variability of patient characteristics, chemotherapeutic 
regimens, histological and molecular subtypes (early trials 
might even have included GIST patients), the variable fol-
low-up and differing definitions of end points all preclude 
the available evidence of chemotherapeutic effectiveness.
Despite the paucity of randomized trials, anthracy-
clines, either as a single-or-multi-agent chemotherapy, 
are the first-line of treatment for abdominal LMS [5], 
according to the ESMO-guidelines. Moreover, depending 
on the histological-subtype, doxorubicin and dacarbazine 
(for a purely LMS) [20] or doxorubicin and ifosfamide 
(for malignancies with a pleomorphic cellular compo-
nent) [21] have been advocated. Second-line chemo-
therapeutic agents recommended include (1) standard 
ifosfamide or high-dose ifosfamide (around 14  g/m2) 
[22], (2) a combination of gemcitabine and docetaxel [23] 
(which showed improved progression free survival and 
overall survival than gemcitabine alone) [24], (3) a com-
bination of dacarbazine and gemcitabine [25] and (4) tra-
bectedin [26]. The rationale for giving the patient such 
intense and sequential chemotherapy has previously been 
shown to be successful [27] in achieving a maximal radio-
logical and clinical response. It has also been reported to 
improve long-term survival [28]. We chose not to use tra-
bectedin and pazopanib as there is not much experience 
with these drugs in a curative treatment setting.
For advanced metastatic disease, surgery or radiofre-
quency ablation is usually not the treatment of choice, 
but may be considered in selected cases where the num-
ber of metastatic foci are few and amenable to interven-
tion. Given the remarkable response of our patient to 
chemotherapy, we decided to remove remaining lesions 
in the lung and liver using surgical resection and radiof-
requency ablation with the hope of achieving long-term, 
complete clinical remission [29]. The rational for such an 
approach is that the smallest lesions, including micro-
metastases, may have been completely eradicated by the 
chemotherapy. Hence, removing the larger metastases, 
which may still contain foci of viable sarcoma cells, elimi-
nates the nidus for subsequent relapse. While the degree 
of response to preoperative chemotherapy has not been 
demonstrated to influence post-resection survival, largely 
due to small sample size, the progression of disease prior 
to resection is a known adverse prognostic factor [30]. 
The presence of disease outside the chest has been con-
sidered a contraindication to resection of pulmonary 
metastases. More recently, however, it has been shown 
that resection of pulmonary and extrapulmonary metas-
tases results in disease-free survival and overall survival, 
similar to that seen in patients who undergo resection of 
metastases limited to the lungs [12].
Conclusions
To our knowledge, this is the first report of a patient 
with metastatic mesenteric LMS who developed com-
plete clinical and radiological remission without any 
demonstrable long-term side effects from chemotherapy, 
after receiving multimodal therapy including an uncon-
ventional histological-subtype-tailored chemotherapy 
comprising 3–4 regimens, surgical resection and radi-
ofrequency ablation of metastatic foci. Given the rar-
ity of mesenteric leiomyosarcoma and lack of guidelines 
regarding oncological therapy, we suggest that multi-
modal therapy including aggressive histological-subtype 
tailored chemotherapy can result in complete remission 
under the guidance of a multidisciplinary team.
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